Sample list of current or past clients:

GlycoMimetics, Inc. — Founded in 2003, GlycoMimetics is developing small molecule drugs targeting unmet clinical needs in orphan disease indications. The company’s lead product, GMI-1070, is initially being developed for the treatment of vaso-occlusive crisis in sickle cell disease and has been granted Orphan Drug and Fast Track Status by the U.S. Food and Drug Administration. The company announced positive topline results from a Phase 2 trial with GMI-1070 in April 2013. For additional information, please visit the company’s web site:

MaxCyte – a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical need in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based breakthrough platform for immuno-oncology. In addition, through its core business, the Company leverages its Flow Electroporation® technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licenses in cell therapy including more than 20 licensed for clinical use in cell therapy. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit

UM BioPark — The BioPark is a biomedical research park on the vibrant academic medical center campus of the University of Maryland, Baltimore (UMB). Its community of life science companies and academic research centers are commercializing new drugs, diagnostics and devices and advancing biomedical research. For more information, please visit,

UM Ventures – a joint initiative of the MPowering the State Program, bringing the University of Maryland, Baltimore and University of Maryland, College Park together to commercialize discoveries, and create economic impact by engaging partners in industry and social ventures. By encouraging  our students and faculty, providing expert advice and business services, more discoveries will reach the market. By engaging directly with external partners we will bring new investment, expanded markets and more startup ventures. The UM Ventures internal Advisory Board was formed in August 2012. Its members are the Deans of Business, Engineering, and Computer, Mathematical and Natural Sciences at UMCP and the Deans of Law, Medicine, and Pharmacy at UMB. The Board is co-chaired by the UMCP Vice President of Research, and UMB Vice President of Enterprise and Economic Development. Learn more at

Learn how PressComm PR has helped others.